,Melanoma 1.pdf,Melanoma 10.pdf,Melanoma 11.pdf,Melanoma 12.pdf,Melanoma 13.pdf,Melanoma 14.pdf,Melanoma 2.pdf,Melanoma 3.pdf,Melanoma 4.pdf,Melanoma 5.pdf,Melanoma 6.pdf,Melanoma 7.pdf,Melanoma 8.pdf,Melanoma 9.pdf
patient,0,0,0,45,0,0,0,0,0,0,0,0,0,0
diagnosis,0,0,0,0,0,0,0,48,0,0,0,0,0,0
microscopy,27,0,0,0,0,0,40,0,24,0,24,27,0,0
dysplastic,0,0,0,0,0,0,0,0,0,29,0,0,0,0
personal,0,0,0,0,0,0,0,0,0,0,0,0,0,120
study,0,32,0,0,0,0,0,0,0,26,0,0,0,0
surveillance,0,0,0,37,0,0,0,0,0,0,0,0,0,0
features,28,0,0,0,0,0,0,77,0,0,0,28,0,0
trial,0,0,0,0,0,0,0,0,0,0,0,0,0,116
pattern,0,0,0,0,0,0,0,0,0,24,0,0,0,0
metastatic,0,0,0,0,0,118,0,0,0,0,0,0,0,0
childhood,0,0,0,0,0,0,0,0,0,0,0,0,41,0
mm,0,0,36,0,0,0,0,47,0,0,0,0,0,0
score,0,0,0,0,0,0,36,0,0,0,0,0,0,0
group,0,0,0,41,0,0,0,0,0,0,0,0,0,0
led,0,0,0,39,0,0,0,0,0,0,0,0,0,0
subjects,0,0,0,0,0,0,0,0,0,0,0,0,22,0
mms,0,0,0,0,0,0,0,54,0,0,0,0,0,0
treatment,0,0,0,0,0,0,0,0,0,0,0,0,0,107
nevus,0,0,0,0,0,0,0,0,0,54,0,0,0,0
001,0,0,0,0,0,0,0,57,0,0,0,0,0,0
tumor,0,0,0,0,73,0,0,0,0,0,0,0,0,0
node,0,0,0,0,0,161,0,0,0,0,0,0,0,0
cell,0,0,0,0,0,0,0,0,23,0,23,0,0,0
wiley,0,0,0,0,0,0,0,0,0,0,0,0,17,0
participants,0,0,0,33,0,0,0,0,0,0,0,0,0,0
bcc,0,0,0,0,0,0,0,34,0,0,0,0,0,0
adjuvant,0,0,0,0,0,0,0,0,0,0,0,0,0,92
treated,0,30,0,0,0,0,0,0,0,0,0,0,0,0
incidence,0,0,129,0,0,0,0,0,0,0,0,0,0,0
age,0,0,75,0,0,0,0,0,0,0,0,0,0,0
lesions,29,0,0,0,0,0,0,42,42,0,42,29,0,0
sun,0,0,0,0,0,0,0,0,0,0,0,0,85,0
case,0,30,0,0,0,0,0,0,0,0,0,0,0,0
cells,85,0,0,0,0,0,94,34,65,0,65,85,0,0
malignant,0,0,0,0,95,0,0,0,0,0,0,0,0,0
conjunctiva,0,0,0,0,121,0,0,0,0,0,0,0,0,0
skin,0,0,0,32,0,0,0,0,0,0,0,0,16,0
overdiagnosis,0,0,45,0,0,0,0,0,0,0,0,0,0,0
ophthalmol,0,0,0,0,113,0,0,0,0,0,0,0,0,0
rcm,37,0,0,0,0,0,51,55,41,0,41,37,0,0
may,0,0,0,0,136,0,0,0,0,0,0,0,0,0
disease,0,0,0,0,0,134,0,0,0,0,0,0,0,0
stage,0,0,0,0,0,152,0,0,0,0,0,0,0,98
pam,0,0,0,0,78,0,0,0,0,0,0,0,0,0
nevi,0,0,0,0,0,0,0,0,25,79,25,0,0,0
category,0,0,0,0,0,120,0,0,0,0,0,0,0,0
2010,0,0,40,0,0,0,0,0,0,0,0,0,0,0
melanocytic,0,0,0,0,0,0,0,0,0,34,0,0,0,0
cohort,0,28,39,0,0,0,0,0,0,0,0,0,0,0
conjunctival,0,0,0,0,261,0,0,0,0,0,0,0,0,0
lymph,0,0,0,0,0,115,0,0,0,0,0,0,0,0
tumors,0,0,0,0,72,0,0,0,0,26,0,0,0,0
confocal,32,0,0,0,0,0,48,0,29,0,29,32,0,0
therapy,0,0,0,0,0,0,0,0,0,0,0,0,0,151
rates,0,0,38,0,0,0,0,0,0,0,0,0,0,0
mortality,0,0,78,0,0,0,0,0,0,0,0,0,0,0
bccs,0,0,0,0,0,0,0,47,0,0,0,0,0,0
transplant,0,26,0,0,0,0,0,0,0,0,0,0,0,0
95,0,0,0,32,0,0,0,0,0,0,0,0,0,0
vivo,28,0,0,0,0,0,38,0,22,0,22,28,0,0
exposure,0,0,0,0,0,0,0,0,0,0,0,0,66,0
clinical,0,0,0,0,0,163,0,0,0,0,0,0,0,0
high,0,0,0,0,0,0,0,0,0,0,0,0,16,0
maligna,0,0,0,0,0,0,37,0,0,0,0,0,0,0
melanomas,36,0,0,0,72,0,0,0,25,0,25,36,0,0
associated,0,0,0,0,0,0,0,0,0,42,0,0,0,0
cancer,0,38,0,0,0,145,0,0,0,0,0,0,0,0
pagetoid,35,0,0,0,0,0,40,0,59,0,59,35,0,0
adulthood,0,0,0,0,0,0,0,0,0,0,0,0,30,0
intervention,0,0,0,50,0,0,0,0,0,0,0,0,0,0
new,0,0,0,30,0,0,0,0,0,0,0,0,0,0
nests,32,0,0,0,0,0,0,0,0,0,0,32,0,0
risk,0,63,0,0,0,0,0,0,0,0,0,0,63,0
melanoma,0,144,124,80,372,384,36,0,0,72,0,0,44,290
ssm,0,0,0,0,0,0,0,0,0,25,0,0,0,0
fees,0,0,0,0,0,0,0,0,0,0,0,0,0,126
years,0,0,43,0,0,0,0,0,0,0,0,0,0,0
nivolumab,0,0,0,0,0,0,0,0,0,0,0,0,0,96
lentigo,0,0,0,0,0,0,42,0,0,0,0,0,0,0
studies,0,35,0,0,0,0,0,0,0,0,0,0,0,0
patients,0,87,0,0,0,311,0,0,0,0,0,0,0,281
